Seaport Therapeutics Advances GlyphAgo into Phase 2a for Anxiety and…

Event summary

First patient dosed in Phase 2a trial of GlyphAgo for generalized anxiety disorder (GAD) and sleep disturbance.
Trial in Australia evaluates two dose levels (16 mg/day and 32 mg/day) of GlyphAgo, a novel prodrug of agomelatine.
Topline data expected in early 2028, with a global Phase 2/3 trial planned for H1 2027.
GlyphAgo aims to improve bioavailability and reduce liver exposure compared to unmodified agomelatine.
Agomelatine has shown superior efficacy and tolerability in meta-analyses compared to benzodiazepines and SSRIs.

The big picture

Seaport Therapeutics is leveraging its Glyph platform to enhance the delivery of agomelatine, a clinically validated anti-anxiety and antidepressant. The Phase 2a trial of GlyphAgo targets a significant unmet need in GAD treatment, particularly for patients experiencing sleep disturbances. With no new therapies approved in nearly two decades, GlyphAgo's success could disrupt the GAD market, which affects over 300 million people globally.

What we're watching

Clinical Efficacy: Whether GlyphAgo can demonstrate superior efficacy and tolerability in GAD patients with sleep disturbance.
Regulatory Pathway: The pace at which Seaport can advance GlyphAgo through Phase 2/3 trials and secure regulatory approval.
Market Differentiation: How GlyphAgo's improved bioavailability and reduced liver exposure could position it against existing GAD treatments.